Eli Lilly’s $12.8 billion obesity bet faces new Medicare test
Eli Lilly (LLY) investors have been struggling to answer a deceptively straightforward question for the last two years. How big can the obesity medicine business get? The answer has already helped produce one of the most powerful growth stories in health care. Lilly’s blockbuster drugs Mounjaro and …
Eli Lilly (LLY) investors have been struggling to answer a deceptively straightforward question for the last two years. How big can the obesity medicine business get? The answer has already helped produce one of the most powerful growth stories in health care. Lilly’s blockbuster drugs Mounjaro and …
Eli Lilly (LLY) investors have been struggling to answer a deceptively straightforward question for the last two years. How big can the obesity medicine business get? The answer has already helped produce one of the most powerful growth stories in health care. Lilly’s blockbuster drugs Mounjaro and …
The full story continues on The Street.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.